Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology

Volumn 139, Issue 3, 2015, Pages 541-545

  Hess, Lisa M ^a   Huang, Helen Q ^b   Hanlon, Alexandra L ^c   Robinson, William R ^d   Johnson, Rhonda ^e   Chambers, Setsuko K ^f   Mannel, Robert S ^g   Puls, Larry ^h   Davidson, Susan A ⁱ   Method, Michael ^j   Lele, Shashikant ^k   Havrilesky, Laura ^l   Nelson, Tina ^g   Alberts, David S ^f  

^a INDIANA UNIVERSITY   (United States)

^b Buffalo Niagara Enterprise   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d TULANE UNIVERSITY   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g UNIVERSITY OF OKLAHOMA   (United States)

^h Greenville CCOP   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j Northern Indiana CCOP   (United States)

^k ROSWELL PARK CANCER INSTITUTE   (United States)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Chemotherapy; Cognitive function; Ovarian cancer; Prospective trial; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; ATTENTION; CANCER CHEMOTHERAPY; COGNITION; COGNITION ASSESSMENT; COGNITIVE DEFECT; COGNITIVE INDEX SCORE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; MOTOR PERFORMANCE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RESPONSE TIME; SCORING SYSTEM; TREATMENT DURATION; UTERINE TUBE; UTERINE TUBE TUMOR; VERY ELDERLY; CHEMICALLY INDUCED; DRUG EFFECTS; FALLOPIAN TUBE NEOPLASMS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PSYCHOLOGY; REACTION TIME; TIME FACTOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ATTENTION; COGNITION; COGNITION DISORDERS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; REACTION TIME; SURVEYS AND QUESTIONNAIRES; TIME FACTORS;

EID: 84949674110     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.10.003     Document Type: Article

References (19)

1. R.O. Hopkins, and J.C. Jackson Long-term neurocognitive function after critical illness Chest 130 2006 869 878
2. I.F. Tannock, T.A. Ahles, P.A. Ganz, and F.S. Van Dam Cognitive impairment associated with chemotherapy for cancer: report of a workshop J. Clin. Oncol. 22 2004 2233 2239
3. D.D. Correa, and T.A. Ahles Neurocognitive changes in cancer survivors Cancer J. 14 2008 396 400
4. K. Hermelink, M. Untch, M.P. Lux, R. Kreienberg, T. Beck, I. Bauerfeind, and et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study Cancer 109 2007 1905 1913
5. S. Taillibert, D. Voillery, and C. Bernard-Marty Chemobrain: is systemic chemotherapy neurotoxic? Curr. Opin. Oncol. 19 2007 623 627
6. R. Wood, and A. Bandura Impact of conceptions of ability on self-regulatory mechanisms and complex decision making J. Pers. Soc. Psychol. 56 1989 407 415
7. A. Medalia, and N. Revheim Dealing with cognitive dysfunction associated with psychiatric disabilities J. Psychiatr. Pract. 10 1 2004 17 25
8. V. Njegovan, M.M. Hing, S.L. Mitchell, and F.J. Molnar The hierarchy of functional loss associated with cognitive decline in older persons J. Gerontol. A Biol. Sci. Med. Sci. 56 2001 M638 6343
9. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
10. S.K. Chambers, and L.M. Hess Ovarian Cancer Prevention D.S. Alberts, L.M. Hess, Fundamentals of Cancer Prevention 2008 Springer Verlag Heidelberg
11. D.D. Correa, and L.M. Hess Cognitive function and quality of life in ovarian cancer Gynecol. Oncol. 124 2012 404 409
12. L.M. Hess, S.K. Chambers, K. Hatch, A. Hallum, M.F. Janicek, J. Buscema, and et al. Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer J Support. Oncol. 8 2010 252 258
13. M.L. Hensley, D.D. Correa, H. Thaler, A. Wilton, E. Venkatraman, P. Sabbatini, and et al. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning Gynecol. Oncol. 102 2006 270 277
14. K. Basen-Engquist, D. Bodurka-Bevers, M.A. Fitzgerald, K. Webster, D. Cella, S. Hu, and et al. Reliability and validity of the functional assessment of cancer therapy - ovarian J. Clin. Oncol. 19 2001 1809 1817
15. E.A. Calhoun, E.E. Welshman, C.H. Chang, J.R. Lurain, D.A. Fishman, T.L. Hunt, and et al. Psychometric evaluation of the functional assessment of cancer therapy/gynecologic oncology group - neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy Int. J. Gynecol. Cancer 13 2003 741 748
16. A.S. Zigmond, and R.P. Snaith The hospital anxiety and depression scale Acta Psychiatr. Scand. 67 1983 361 370
17. D.M. Erlanger, T. Kaushik, D. Broshek, J. Freeman, D. Feldman, and J. Festa Development and validation of a web-based screening tool for monitoring cognitive status J. Head Trauma Rehabil. 17 2002 458 476
18. G.J. Chelune, R.K. Heaton, and R.A. Lehman Neuropsychological and personality correlates of patients' complaints of disability G. Goldstein, R.E. Tarter, Advances in Clinical Neuropsychology 1986 Plenum Press New York
19. C.A. Meyers, and J.S. Wefel The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity J. Clin. Oncol. 21 2003 3557 3558